Tixagevimab and Cilgavimab are a new monoclonal antibody combination authorized for emergency use for the prevention of COVID-19 in certain patients. This learning activity will include a review of the clinical trial data supporting the emergency use authorization of tixagevimab/cilgavimab and also review the indications and contraindications of the monoclonal antibody combination. The activity will also cover recognition and treatment of administration-related reactions to monoclonal antibody injections.
Pharmacists and pharmacy technicians seeking information on clinical use of tixagevimab/cilgavimab for prevention of COVID-19 in specific patients.
- Describe the role of tixagevimab/cilgavimab in the prevention of COVID-19.
- Describe contraindications and precautions to use of tixagevimab/cilgavimab for COVID-19.
- Describe possible administration-related reactions to injection of tixagevimab/cilgavimab.
- Introduction and Announcements
- Questions, Answers, and Discussion
- Michael Ganio, PharmD, MS, BCSCP, FASHP, Senior Director Pharmacy Practice and Quality, ASHP
- Hugh Montgomery, MD, Phase III clinical trial principal investigator
In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.
An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.
No one in control of the content of this activity has a relevant financial relationship (RFR) with an ineligible company.
This activity consists of recordings of faculty slides presentations with embedded self- assessment. Participants must participate in the activity in its entirety to claim continuing pharmacy education credit online at ASHP eLearning Portal. Follow the prompts online to complete the evaluation, claim credit, and view the statement of credit immediately after completing the activity.
Per ACPE requirements, CPE credit must be claimed within 60 days of being earned. Claim your CE at http://elearning.ashp.org. Once you have processed and claimed your CE credit, we encourage you to check your NABP eProfile account to verify your credits were transferred successfully before the ACPE 60-day deadline. It is an electronic direct-report process so your credits should appear in your account within a few minutes. After the 60 day deadline, ASHP will no longer be able to report your credit(s) for this activity.